Canopy Growth Corporation

NASDAQ:CGC

Drug Manufacturers - Specialty & Generic

Healthcare
$0.50 +1.07%

+$0.01 today

Market cap
$212.31M
Beta
0.78
P/E (TTM)
-1.8
EPS (TTM)
-$0.76
52W Low $0.84High $2.38

Volume 3.44M

Average 9.97M

CGC Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Canopy Growth CorporationNASDAQ: CGC

Research & Development · Q4 FY2025 · quarter ended Mar 2026

Research & development remains negative

Q4 FY2025 research & development was CA$0, compared with CA$2.74M a year earlier. Trailing-twelve-month research & development was CA$0.

Context

  • Research & development amounted to 0.0% of revenue in FY2025, down 0.7 pp from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly research & development holds near CA$0 or moves back toward the trailing-twelve-month quarterly average of CA$0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$0— QoQ
Last fiscal yearMar 2026
CA$0-100.0% YoY
LTMMar 2026
CA$0-100.0% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

CAD · from the income statement

Latest · FY2025
0 CAD
Year-over-year change
-100.0%

Research & Development vs competitors

How CGC compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -100.0% is the lowest of 9, against a peer median of +13.7%.
  • Research & development amounts to 0.0% of revenue for CGC, versus a peer median of 18.9%.
CGC Competitors
Research & Development for CGC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LYELLyell Immunopharma, Inc.LTM Mar 2026$151.83M USD-11.7%-0.1%489780.6%
CABACabaletta Bio, Inc.LTM Mar 2026$151.01M USD+44.8%+53.7%—
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 2026$88.26M USD-21.9%+29.1%24.4%
BIOABioAge Labs, Inc.LTM Mar 2026$83.27M USD+36.9%+34.3%807.2%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$56.72M USD+60.6%-12.2%677.9%
DHDefinitive Healthcare Corp.LTM Mar 2026$31.97M USD-10.4%-0.1%13.4%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$7.58M USD—+1.8%5.6%
ACBAurora Cannabis Inc.LTM Mar 2026CA$4.98M CAD+35.4%+1.4%1.6%
TKNOAlpha Teknova, Inc.LTM Mar 2026$2.25M USD-8.0%-34.3%5.4%
CGCCanopy Growth CorporationLTM Mar 2026CA$0 CAD-100.0%—0.0%
Peer median (excluding CGC) —+13.7%+1.4%18.9%

Competitors are the stored peer set for CGC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Mar 2022
FY2022
Mar 2023
FY2023
Mar 2024
FY2024
Mar 2025
FY2025
Mar 2026
Revenue475.7M333.25M297.15M269M483.67M
Cost of Revenue663.11M396.78M216.26M189.48M386.51M
Gross Profit(187.41M)(63.53M)80.88M79.51M97.16M
Gross Margin-39.4%-19.1%27.2%29.6%20.1%
Research & Development32.26M21.72M4.61M1.91M0
Selling, General & Admin361.1M297.98M180.59M121.71M223.11M
Operating Expenses831.39M2.57B309.6M196.65M322.6M
Depreciation & Amortization110.94M80.03M53.18M43.12M50.86M
EBITDA(52.98M)(2.88B)(312.83M)(479.31M)50.86M
EBITDA Margin-11.1%-864.2%-105.3%-178.2%10.5%
Operating Income(1.02B)(2.63B)(228.71M)(117.14M)(161.66M)
Operating Margin-214.2%-789.3%-77.0%-43.5%-33.4%
Interest Income6.6M24.28M16.24M8.82M10M
Interest Expense103.94M126.16M105.35M74.57M38.19M
Other Income / Expenses750.94M(455.64M)(242.64M)(479.85M)(101.23M)
Income Before Tax(267.86M)(3.09B)(471.36M)(597M)(262.89M)
Pre-Tax Margin-56.3%-926.1%-158.6%-221.9%-54.4%
Income Tax Expense(8.95M)(5.73M)12.33M7.14M23K
Net Income(310.04M)(3.28B)(657.27M)(598.12M)(366.64M)
Net Margin-65.2%-983.7%-221.2%-222.4%-75.8%
EPS (Basic)(7.70)(70.70)(6.47)(5.53)(0.88)
EPS (Diluted)(7.70)(70.70)(8.79)(5.53)(0.88)
Weighted Avg Shares39.13M46.37M101.63M107.55M2.98B
Weighted Avg Shares (Diluted)39.13M46.37M74.79M107.55M2.98B

Canopy Growth Corporation

NASDAQ:CGC

Intrinsic Alpha fair value

Locked

Current Price

$0.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.